drug_type
RELEVANT_DRUG
intervention_type
antibody-drug conjugate
drug_description
HER2-targeted antibody–drug conjugate of trastuzumab linked to the maytansinoid DM1 microtubule inhibitor; delivers cytotoxic payload to HER2-overexpressing cells while retaining trastuzumab activity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Ado-Trastuzumab Emtansine
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Ado-trastuzumab emtansine (T-DM1) is a HER2-targeted antibody–drug conjugate in which trastuzumab is linked to the microtubule inhibitor DM1. It binds HER2 on tumor cells, is internalized, and releases DM1 to disrupt microtubules and induce cell death, while trastuzumab concurrently inhibits HER2 signaling and mediates ADCC.
drug_name
Ado-trastuzumab emtansine (T-DM1)
nct_id_drug_ref
NCT06663787